TENX News and Press, Tenax Therapeutics Inc. From 09/16/25

Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103 (Oral Levosimendan) and Other Drug Formulations, and its Active Metabolites, in PH-HFpEF Also Provides Patent Protection for Wide Range of Levosimendan Doses, and its Use in Combi...

CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced...

2025-08-13 16:30:42 ET More on Tenax Therapeutics Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Tenax Therapeutics Financial information for Tenax Therapeutics Read the full article on Seeking Alpha For further...

Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 CHAPEL HILL, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, In...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...

Tenax Therapeutics Inc. (TENX) is expected to report $-0.5 for Q2 2025

2025-05-14 17:43:52 ET More on Tenax Therapeutics Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts Tenax Therapeutics announces $25M private placement Seeking Alpha’s Quant Rating on Tenax Therapeutics Historical earnings data for Te...

Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 Initiation of Second Phase 3 Study, LEVEL-2, Expected This Year CHAPEL HILL, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: ...

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

2025-04-22 21:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...